Screener / SEC EDGAR /CIK 0001759425 /10-K filed Feb 25, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Mirum Pharmaceuticals, Inc. MIRM

Compare with peers Embed

MIRM among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
+54.7%15th of 155 · median +10.5%
Net margin
-4.1%15.3%
-134.8%146th of 154 · median 6.8%
Free cash flow margin
2.3%19.2%
-40.8%131st of 145 · median 10.0%

MIRM and 9 peers, year by year

The 9 Health care companies closest to MIRM in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthGross marginOperating marginNet marginFCF marginReturn on equityDebt / equity
MIRM Mirum Pharmaceuticals, Inc. FY2025 $521.3M+54.7%-−4.2%−4.5%10.5%−7.4%-
TARS Tarsus Pharmaceuticals, Inc. FY2025 $451.4M+147%-−15.7%−14.7%−4.9%−19.3%0.21
GKOS GLAUKOS Corp FY2025 $507.4M+32.3%55.7%−39.3%−37.0%−4.4%−28.6%-
UFPT UFP Technologies Inc FY2025 $602.8M+19.5%28.3%15.3%11.3%-16.1%0.32
TMDX TransMedics Group, Inc. FY2025 $605.5M+37.1%59.9%17.9%31.4%22.1%40.2%-
RARE Ultragenyx Pharmaceutical Inc. FY2025 $673.0M+20.2%-−79.5%−85.4%−70.1%n/m-
VCYT Veracyte, Inc. FY2025 $517.1M+16.0%70.1%11.2%12.8%24.5%5.1%-
PTGX Protagonist Therapeutics, Inc FY2025 $46.0M−89.4%-−343.6%−282.8%121.9%−21.2%-
RGEN Repligen Corp FY2025 $738.3M+16.4%-7.5%6.6%12.7%2.3%0.26
ADMA Adma Biologics, Inc. FY2025 $510.2M+19.6%57.4%37.5%28.8%5.5%30.8%0.15

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2019 to FY2025 · 10-K XBRL

MIRMMirum Pharmaceuticals, Inc.
FY2021 revenue $19.1MFY2022 revenue $77.1MFY2023 revenue $186.4MFY2024 revenue $336.9MFY2025 revenue $521.3M FY2021 net margin −438.9%FY2022 net margin −176.0%FY2023 net margin −87.7%FY2024 net margin −26.1%FY2025 net margin −4.5% FY2019FY2025
Revenue$521.3M Growth+54.7% Net margin−4.5%
TARSTarsus Pharmaceuticals, Inc.
FY2021 revenue $57.0MFY2022 revenue $25.8MFY2023 revenue $17.4MFY2024 revenue $183.0MFY2025 revenue $451.4M FY2021 net margin −24.2%FY2022 net margin −240.5%FY2023 net margin −778.9%FY2024 net margin −63.2%FY2025 net margin −14.7% FY2019FY2025
Revenue$451.4M Growth+147% Net margin−14.7%
GKOSGLAUKOS Corp
FY2019 revenue $237.0MFY2020 revenue $225.0MFY2021 revenue $294.0MFY2022 revenue $282.9MFY2023 revenue $314.7MFY2024 revenue $383.5MFY2025 revenue $507.4M FY2019 net margin 6.5%FY2020 net margin −53.5%FY2021 net margin −16.9%FY2022 net margin −35.1%FY2023 net margin −42.8%FY2024 net margin −38.2%FY2025 net margin −37.0% FY2019FY2025
Revenue$507.4M Growth+32.3% Net margin−37.0%
UFPTUFP Technologies Inc
FY2019 revenue $198.4MFY2020 revenue $179.4MFY2021 revenue $206.3MFY2022 revenue $353.8MFY2023 revenue $400.1MFY2024 revenue $504.4MFY2025 revenue $602.8M FY2019 net margin 10.0%FY2020 net margin 7.5%FY2021 net margin 7.7%FY2022 net margin 11.8%FY2023 net margin 11.2%FY2024 net margin 11.7%FY2025 net margin 11.3% FY2019FY2025
Revenue$602.8M Growth+19.5% Net margin11.3%
TMDXTransMedics Group, Inc.
FY2019 revenue $25.8MFY2020 revenue $28.4MFY2021 revenue $31.4MFY2022 revenue $93.5MFY2023 revenue $241.6MFY2024 revenue $441.5MFY2025 revenue $605.5M FY2019 net margin −129.8%FY2020 net margin −101.4%FY2021 net margin −140.9%FY2022 net margin −38.8%FY2023 net margin −10.4%FY2024 net margin 8.0%FY2025 net margin 31.4% FY2019FY2025
Revenue$605.5M Growth+37.1% Net margin31.4%
RAREUltragenyx Pharmaceutical Inc.
FY2019 revenue $103.7MFY2020 revenue $271.0MFY2021 revenue $351.4MFY2022 revenue $363.3MFY2023 revenue $434.0MFY2024 revenue $560.0MFY2025 revenue $673.0M FY2019 net margin −388.3%FY2020 net margin −68.8%FY2021 net margin −129.2%FY2022 net margin −194.7%FY2023 net margin −139.9%FY2024 net margin −101.6%FY2025 net margin −85.4% FY2019FY2025
Revenue$673.0M Growth+20.2% Net margin−85.4%
VCYTVeracyte, Inc.
FY2019 revenue $120.4MFY2020 revenue $117.5MFY2021 revenue $219.5MFY2022 revenue $296.5MFY2023 revenue $361.1MFY2024 revenue $445.8MFY2025 revenue $517.1M FY2019 net margin −10.5%FY2020 net margin −29.7%FY2021 net margin −34.4%FY2022 net margin −12.3%FY2023 net margin −20.6%FY2024 net margin 5.4%FY2025 net margin 12.8% FY2019FY2025
Revenue$517.1M Growth+16.0% Net margin12.8%
PTGXProtagonist Therapeutics, Inc
FY2019 revenue $231KFY2020 revenue $28.6MFY2021 revenue $27.4MFY2022 revenue $26.6MFY2023 revenue $60.0MFY2024 revenue $434.4MFY2025 revenue $46.0M FY2020 net margin −231.1%FY2021 net margin −458.9%FY2022 net margin −479.3%FY2023 net margin −131.6%FY2024 net margin 63.3%FY2025 net margin −282.8% FY2019FY2025
Revenue$46.0M Growth−89.4% Net margin−282.8%
RGENRepligen Corp
FY2019 revenue $270.2MFY2020 revenue $366.3MFY2021 revenue $670.5MFY2022 revenue $801.5MFY2023 revenue $632.4MFY2024 revenue $634.4MFY2025 revenue $738.3M FY2019 net margin 7.9%FY2020 net margin 16.4%FY2021 net margin 19.1%FY2022 net margin 23.2%FY2023 net margin 5.6%FY2024 net margin −4.0%FY2025 net margin 6.6% FY2019FY2025
Revenue$738.3M Growth+16.4% Net margin6.6%
ADMAAdma Biologics, Inc.
FY2019 revenue $29.3MFY2020 revenue $42.2MFY2021 revenue $80.9MFY2022 revenue $154.1MFY2023 revenue $258.2MFY2024 revenue $426.5MFY2025 revenue $510.2M FY2019 net margin −164.5%FY2020 net margin −179.4%FY2021 net margin −88.5%FY2022 net margin −42.8%FY2023 net margin −10.9%FY2024 net margin 46.4%FY2025 net margin 28.8% FY2019FY2025
Revenue$510.2M Growth+19.6% Net margin28.8%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2019 to FY2025

Revenue as reported in the 10-K.

$0 $801.5M FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TARS: -, $0, $57.0M, $25.8M, $17.4M, $183.0M, $451.4M TARS GKOS: $237.0M, $225.0M, $294.0M, $282.9M, $314.7M, $383.5M, $507.4M GKOS UFPT: $198.4M, $179.4M, $206.3M, $353.8M, $400.1M, $504.4M, $602.8M UFPT TMDX: $25.8M, $28.4M, $31.4M, $93.5M, $241.6M, $441.5M, $605.5M TMDX RARE: $103.7M, $271.0M, $351.4M, $363.3M, $434.0M, $560.0M, $673.0M RARE VCYT: $120.4M, $117.5M, $219.5M, $296.5M, $361.1M, $445.8M, $517.1M VCYT PTGX: $231K, $28.6M, $27.4M, $26.6M, $60.0M, $434.4M, $46.0M PTGX RGEN: $270.2M, $366.3M, $670.5M, $801.5M, $632.4M, $634.4M, $738.3M RGEN ADMA: $29.3M, $42.2M, $80.9M, $154.1M, $258.2M, $426.5M, $510.2M ADMA MIRM: -, $0, $19.1M, $77.1M, $186.4M, $336.9M, $521.3M MIRM
MIRM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from $0 to $801.5M. A gap is a year with no number. A ring marks where a line starts: MIRM, TARS have no earlier 10-K here.

Sales growth, FY2019 to FY2025

Revenue against the fiscal year before.

−99.3% +949% FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TARS: -, -, -, −54.7%, −32.4%, +949%, +147% TARS GKOS: +30.7%, −5.1%, +30.7%, −3.8%, +11.3%, +21.9%, +32.3% GKOS UFPT: +4.2%, −9.6%, +15.0%, +71.5%, +13.1%, +26.1%, +19.5% UFPT TMDX: +76.3%, +9.7%, +18.0%, +209%, +159%, +82.7%, +37.1% TMDX RARE: +101%, +161%, +29.7%, +3.4%, +19.5%, +29.0%, +20.2% RARE VCYT: +30.8%, −2.4%, +86.8%, +35.1%, +21.8%, +23.5%, +16.0% VCYT PTGX: −99.3%, n/m, −4.4%, −2.8%, +126%, +624%, −89.4% PTGX RGEN: +39.3%, +35.5%, +83.1%, +19.5%, −21.1%, +0.3%, +16.4% RGEN ADMA: +72.8%, +43.9%, +91.7%, +90.4%, +67.6%, +65.2%, +19.6% ADMA MIRM: -, -, -, +303%, +142%, +80.8%, +54.7% MIRM
MIRM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −99.3% to +949%. A gap is a year with no number. A ring marks where a line starts: MIRM, TARS have no earlier 10-K here.

Gross margin, FY2019 to FY2025

Gross profit / revenue.

−45.2% 83.7% FY2019FY2020FY2021FY2022FY2023FY2024FY2025 GKOS: 83.7%, 59.2%, 77.3%, 75.6%, 76.0%, 75.5%, 55.7% GKOS UFPT: 27.2%, 24.9%, 24.8%, 25.5%, 28.1%, 29.1%, 28.3% UFPT TMDX: 53.6%, 58.7%, 67.4%, 69.8%, 63.8%, 59.4%, 59.9% TMDX VCYT: -, -, -, 59.2%, 63.6%, 66.9%, 70.1% VCYT ADMA: -, −45.2%, 1.4%, 22.9%, 34.4%, 51.5%, 57.4% ADMA
MIRM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −45.2% to 83.7%. A gap is a year with no number. A ring marks where a line starts: VCYT, ADMA have no earlier 10-K here.
CompanyFY2019FY2020FY2021FY2022FY2023FY2024FY2025
MIRM Dec -------
TARS Dec -------
GKOS Dec 83.7%59.2%77.3%75.6%76.0%75.5%55.7%
UFPT Dec 27.2%24.9%24.8%25.5%28.1%29.1%28.3%
TMDX Dec 53.6%58.7%67.4%69.8%63.8%59.4%59.9%
RARE Dec -------
VCYT Dec ---59.2%63.6%66.9%70.1%
PTGX Dec -------
RGEN Dec -------
ADMA Dec -−45.2%1.4%22.9%34.4%51.5%57.4%
Peer median53.6%41.8%46.1%59.2%63.6%59.4%57.4%

Operating margin, FY2019 to FY2025

Operating income / revenue.

−906.1% 58.2% FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TARS: -, -, −21.3%, −242.9%, −820.5%, −65.9%, −15.7% TARS GKOS: −21.2%, −54.9%, −11.2%, −29.1%, −40.9%, −31.9%, −39.3% GKOS UFPT: 12.5%, 9.3%, 10.3%, 15.7%, 14.4%, 16.0%, 15.3% UFPT TMDX: −114.5%, −93.0%, −125.6%, −33.6%, −11.9%, 8.5%, 17.9% TMDX RARE: −409.0%, −121.8%, −108.6%, −178.6%, −131.1%, −95.7%, −79.5% RARE VCYT: −12.6%, −30.1%, −37.3%, −13.9%, −23.8%, 3.6%, 11.2% VCYT PTGX: n/m, −225.4%, −460.0%, −494.2%, −156.1%, 58.2%, −343.6% PTGX RGEN: 13.4%, 19.1%, 24.9%, 28.0%, 7.5%, −5.5%, 7.5% RGEN ADMA: −141.1%, −153.8%, −72.1%, −25.5%, 8.4%, 32.6%, 37.5% ADMA MIRM: -, -, −906.1%, −170.3%, −58.6%, −26.0%, −4.2% MIRM
MIRM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −906.1% to 58.2%. A gap is a year with no number. A ring marks where a line starts: MIRM, TARS, PTGX have no earlier 10-K here.

Net margin, FY2019 to FY2025

Net income / revenue.

−778.9% 63.3% FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TARS: -, -, −24.2%, −240.5%, −778.9%, −63.2%, −14.7% TARS GKOS: 6.5%, −53.5%, −16.9%, −35.1%, −42.8%, −38.2%, −37.0% GKOS UFPT: 10.0%, 7.5%, 7.7%, 11.8%, 11.2%, 11.7%, 11.3% UFPT TMDX: −129.8%, −101.4%, −140.9%, −38.8%, −10.4%, 8.0%, 31.4% TMDX RARE: −388.3%, −68.8%, −129.2%, −194.7%, −139.9%, −101.6%, −85.4% RARE VCYT: −10.5%, −29.7%, −34.4%, −12.3%, −20.6%, 5.4%, 12.8% VCYT PTGX: n/m, −231.1%, −458.9%, −479.3%, −131.6%, 63.3%, −282.8% PTGX RGEN: 7.9%, 16.4%, 19.1%, 23.2%, 5.6%, −4.0%, 6.6% RGEN ADMA: −164.5%, −179.4%, −88.5%, −42.8%, −10.9%, 46.4%, 28.8% ADMA MIRM: -, -, −438.9%, −176.0%, −87.7%, −26.1%, −4.5% MIRM
MIRM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −778.9% to 63.3%. A gap is a year with no number. A ring marks where a line starts: MIRM, TARS, PTGX have no earlier 10-K here.

Free cash flow, FY2019 to FY2025

Cash from operations minus capital spending.

−$519.0M $182.8M FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TARS: −$3.8M, −$21.6M, $3.2M, −$49.5M, −$119.0M, −$84.6M, −$22.3M TARS GKOS: −$5.1M, −$29.9M, −$23.1M, −$63.3M, −$78.0M, −$67.6M, −$22.5M GKOS UFPT: $25.5M, $20.7M, $8.9M, $4.0M, $30.8M, $56.9M, - UFPT TMDX: −$32.5M, −$30.7M, −$32.4M, −$57.7M, −$164.9M, −$80.9M, $133.6M TMDX RARE: −$370.2M, −$176.1M, −$411.8M, −$496.6M, −$519.0M, −$421.0M, −$472.0M RARE VCYT: −$6.0M, −$12.5M, −$37.0M, −$1.0M, $34.3M, $63.8M, $126.6M VCYT PTGX: −$42.5M, −$73.0M, −$109.0M, −$108.9M, −$70.8M, $182.8M, $56.1M PTGX RGEN: $48.7M, $40.2M, $51.9M, $87.2M, $77.7M, $149.7M, $93.9M RGEN ADMA: −$80.0M, −$114.7M, −$125.9M, −$73.4M, $4.0M, $110.4M, $27.8M ADMA MIRM: −$39.6M, −$89.3M, −$132.8M, −$120.4M, −$71.1M, $9.3M, $54.9M MIRM
MIRM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$519.0M to $182.8M. A gap is a year with no number.

FCF margin, FY2019 to FY2025

Free cash flow / revenue.

−693.8% 121.9% FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TARS: -, -, 5.5%, −191.9%, −682.0%, −46.2%, −4.9% TARS GKOS: −2.1%, −13.3%, −7.8%, −22.4%, −24.8%, −17.6%, −4.4% GKOS UFPT: 12.8%, 11.5%, 4.3%, 1.1%, 7.7%, 11.3%, - UFPT TMDX: −125.6%, −108.3%, −103.2%, −61.8%, −68.2%, −18.3%, 22.1% TMDX RARE: −357.0%, −65.0%, −117.2%, −136.7%, −119.6%, −75.2%, −70.1% RARE VCYT: −5.0%, −10.7%, −16.9%, −0.3%, 9.5%, 14.3%, 24.5% VCYT PTGX: n/m, −254.8%, −398.3%, −409.8%, −118.1%, 42.1%, 121.9% PTGX RGEN: 18.0%, 11.0%, 7.7%, 10.9%, 12.3%, 23.6%, 12.7% RGEN ADMA: −272.6%, −271.7%, −155.5%, −47.6%, 1.6%, 25.9%, 5.5% ADMA MIRM: -, -, −693.8%, −156.3%, −38.1%, 2.8%, 10.5% MIRM
MIRM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −693.8% to 121.9%. A gap is a year with no number. A ring marks where a line starts: MIRM, TARS, PTGX have no earlier 10-K here.

Return on equity, FY2019 to FY2025

Net income / shareholders' equity at the year end.

−184.3% 56.6% FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TARS: n/m, −16.2%, −8.3%, −32.2%, −69.0%, −51.5%, −19.3% TARS GKOS: 2.3%, −18.0%, −8.4%, −18.7%, −29.2%, −19.1%, −28.6% GKOS UFPT: 12.2%, 7.6%, 8.2%, 17.6%, 15.7%, 17.2%, 16.1% UFPT TMDX: −61.4%, −27.7%, −65.2%, −19.3%, −18.2%, 15.5%, 40.2% TMDX RARE: −61.6%, −16.2%, −49.2%, n/m, n/m, n/m, n/m RARE VCYT: −5.3%, −8.3%, −6.9%, −3.4%, −7.1%, 2.1%, 5.1% VCYT PTGX: −96.5%, −23.7%, −41.8%, −59.1%, −23.5%, 40.8%, −21.2% PTGX RGEN: 2.0%, 3.9%, 7.3%, 9.7%, 1.8%, −1.3%, 2.3% RGEN ADMA: −184.3%, −85.8%, −50.8%, −43.4%, −20.9%, 56.6%, 30.8% ADMA MIRM: −40.3%, −60.0%, −69.9%, −95.5%, −65.7%, −39.0%, −7.4% MIRM
MIRM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −184.3% to 56.6%. A gap is a year with no number. A ring marks where a line starts: TARS has no earlier 10-K here.

Debt / equity, FY2019 to FY2025

Total debt / shareholders' equity at the year end.

0.00 1.05 FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TARS: -, -, 0.00, 0.10, 0.15, 0.32, 0.21 TARS UFPT: -, 0.00, 0.39, 0.23, 0.11, 0.55, 0.32 UFPT TMDX: 0.62, 0.33, 0.52, 0.31, -, -, - TMDX VCYT: 0.00, 0.00, 0.00, -, -, -, - VCYT PTGX: 0.12, -, -, -, -, -, - PTGX RGEN: -, -, -, -, -, 0.27, 0.26 RGEN ADMA: 0.00, 1.05, -, -, -, 0.21, 0.15 ADMA
MIRM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.00 to 1.05. A gap is a year with no number. A ring marks where a line starts: TARS, UFPT, RGEN have no earlier 10-K here.
CompanyFY2019FY2020FY2021FY2022FY2023FY2024FY2025
MIRM Dec -------
TARS Dec --0.000.100.150.320.21
GKOS Dec -------
UFPT Dec -0.000.390.230.110.550.32
TMDX Dec 0.620.330.520.31---
RARE Dec -------
VCYT Dec 0.000.000.00----
PTGX Dec 0.12------
RGEN Dec -----0.270.26
ADMA Dec 0.001.05---0.210.15
Peer median0.060.170.190.23-0.290.23

EPS (diluted), FY2019 to FY2025

Diluted earnings per share, on today's share count after splits.

−$10.12 $8.75 FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TARS: −$1.98, −$4.32, −$0.67, −$2.52, −$4.62, −$3.07, −$1.59 TARS GKOS: $0.37, −$2.70, −$1.07, −$2.09, −$2.78, −$2.77, −$3.28 GKOS UFPT: $2.63, $1.77, $2.09, $5.45, $5.83, $7.58, $8.75 UFPT TMDX: −$2.36, −$1.16, −$1.60, −$1.23, −$0.77, $1.01, $4.87 TMDX RARE: −$7.12, −$3.07, −$6.70, −$10.12, −$8.25, −$6.29, −$5.83 RARE VCYT: −$0.27, −$0.66, −$1.11, −$0.51, −$1.02, $0.31, $0.82 VCYT PTGX: −$2.98, −$1.92, −$2.71, −$2.60, −$1.39, $4.23, −$2.05 PTGX RGEN: $0.44, $1.11, $2.24, $3.24, $0.63, −$0.46, $0.86 RGEN ADMA: −$0.89, −$0.88, −$0.51, −$0.33, −$0.13, $0.81, $0.60 ADMA MIRM: −$4.58, −$4.09, −$2.77, −$4.02, −$4.00, −$1.85, −$0.47 MIRM
MIRM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$10.12 to $8.75. A gap is a year with no number.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out MIRM and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: MIRM's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MIRM/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.